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Genetic risk factor characterizes abdominal aortic
aneurysm from arterial occlusive disease in human
beings: CCR5 32 deletion
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Objective: Inflammation is involved in the pathogenesis of atherosclerosis and abdominal aortic aneurysm (AAA), and
chemokines are mediators of the inflammatory process. The homozygous 32 deletion mutation of the gene of the
chemokine receptor CCR5 is a cause of its lack in inflammatory cells. The purpose of this study was to investigate the
relationship between CCR5 32 deletion mutation and AAA, peripheral arterial occlusive disease (PAOD), and carotid
stenosis.
Methods: The CCR5 32 polymorphism was genotyped in 380 subjects: 70 patients operated on to treat AAA (21
ruptured AAAs, 49 elective repair), 76 patients with PAOD, 62 patients with carotid stenosis, and 172 age-matched and
sex-matched healthy control subjects. Risk factors for AAA were considered. Each patient was assessed according to a
diagnostic procedure tailored to symptoms at presentation.
Results: In patients with AAA the  allelic variation was significantly different compared with control subjects (P .002;
odds ratio [OR], 2.7; 95% confidence interval [CI], 1.41-5.15). The increased presence of this allele differentiates AAA
from both PAOD (P .017; OR, 2.77; 95% CI, 1.17-6.52) and carotid stenosis (P .01; OR, 3.47; 95% CI, 1.31-9.11).
The presence in the genotype of patients with AAA of at least 1 32 allele is more frequent in ruptured AAAs than in
electively repaired AAAs (genotype: OR, 4.04; 95% CI, 1.34-12.1; P  .011; allelic frequency: OR, 2.75; 95% CI,
1.07-7.07; P .035). Among the patients, multiple regression analysis showed that the 32 allele is an independent risk
factor for AAA vs PAOD (OR, 3.13; 95% CI, 1.33-7.33; P  .012) and for ruptured AAAs vs electively repaired AAAs
(OR, 3.52; 95% CI, 1.01-11.80; P  .045).
Conclusions: CCR5 32 deletion mutation is significantly more frequent in patients with AAA than in control subjects
and in both patients with PAOD and carotid stenosis, and could be a factor that differentiates AAA from PAOD, and
ruptured AAAs from AAAs that can be electively repaired. (J Vasc Surg 2004;40:995-1000.)
Clinical Relevance: The major threat of abdominal aortic aneurysm (AAA) is rupture, accounting for extremely high
mortality. This occurrence has been correlated to aneurysm size, but it is a common observation that small AAAs can
rupture and large AAAs can remain stable for many years. This study was carried out in an attempt to search for genetic
markers of aneurysm rupture. Some single nucleotide polymorphisms are implicated in acceleration of transcription for
enzymes involved in the inflammatory process and in extracellular matrix remodeling. An association between single
nucleotide polymorphisms and aneurysm rupture could enable better selection for surgical indications in patients with
small AAAs and in patients at poor risk with large AAAs.Abdominal aortic aneurysms (AAA) are common in the
aging populations of industrialized nations, with estimates
of prevalence as high as 10%. AAA rupture accounts for
approximately 4% of all deaths in persons older than 65
years.
Despite the high risk for death associated with AAA,
few definitive risk factors have been identified. The se-
quence of biochemical and cellular events in the evolution
of AAAs in human beings is largely unknown. AAA is often
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doi:10.1016/j.jvs.2004.08.014associated with atherosclerosis; however, there are certain
pathogenetic, epidemiologic, and genetic differences be-
tween the 2 diseases.1,2 The basic phenomena in the patho-
genesis of AAA are degradation of the extracellular matrix
components (elastin, collagens) and loss of the structural
integrity of the aortic wall.1,2 AAA disease typically involves
tissue inflammation, as noted by the presence of inflamma-
tory leukocytes and various cytokines, which are considered
relevant in the immunopathogenesis of AAA, leading to
destruction of the aortic matrix.1-3 Prominent inflamma-
tory infiltrates of macrophages and lymphocytes are found
in both peripheral arterial occlusive disease (PAOD) and
AAA.4,5
Chemokines are cytokines that promote migration of
leukocytes into inflammatory sites, and their differentiation
or activation.6 In recent years their role in the pathogenesis
of several immune-mediated diseases has been recognized.7
Moreover, polymorphisms in gene encoding chemokines
and their receptors (ie, CCR5, CCR2, stromal cell–derived
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virus infection and inflammatory diseases.8-10
CCR5 is a chemokine receptor that could potentially be
involved in plaque development. CCR5 is expressed on
macrophages, T cells, aortic smooth muscle cells, and cor-
onary endothelial cells11-14; CCR5 ligands have been de-
tected in plaques.15 Furthermore, recent genetic screening
studies showed that natural deficiency in CCR5 protects
against early myocardial infarction16 and severe coronary
artery disease.17 A common 32-base pair deletion mutation
in the CCR5 gene (32) that causes truncation and loss of
CCR5 receptors on lymphoid cell surfaces of homozygotes
was recently described.8
The purpose of this study was to compare CCR5 geno-
types between patients with AAA, and patients with PAOD
or internal carotid artery stenosis.
MATERIAL AND METHODS
The present study included 4 groups of patients con-
secutively recruited during routine examination through
the year 2002: 70 patients with AAA, 76 patients with
PAOD, and 62 patients with carotid stenosis.
Control subjects consisted of 172 volunteers consecu-
tively recruited in the same period from outpatients re-
ferred to our vascular laboratory who did not have clinically
or ultrasound-detected atherosclerosis.
Within the group of patients with AAA, 21 were con-
secutively admitted to the Emergency Department of San
Paolo Hospital, Milan, Italy, with ruptured aneurysms
(ruptured AAA group). Forty-nine patients with AAA
(elective AAA group) and all patients with PAOD or ca-
rotid stenosis were consecutively admitted to our vascular
surgery unit. Each patient, with the exception of the rup-
tured AAA group, was assessed according to a diagnostic
procedure tailored to symptoms at presentation. Once as-
sessment of the admission disease was completed, noninva-
sive ultrasound evaluation of other vascular regions was
performed.
Doppler ultrasound scanning (color flow Doppler im-
aging) was used to assess the abdominal aorta and the
carotid, renal, iliac, femoral, popliteal, and tibial arteries.
When appropriate, coronary flow was assessed with stress
electrocardiography, echocardiography, and myocardial
scintigraphy. All patients with hypertension underwent
routine renal artery echo Doppler ultrasound scanning.
Inclusion criteria were as follows: (1) Asymptomatic
vascular areas were included when arterial stenosis exceed-
ing 50% was documented with color flow imaging. (2)
Angiographic assessment of PAOD was carried out in pa-
tients with disabling or severe claudication (Fontain stages
IIa and IIb), rest pain, or gangrene (Fontain stages III and
IV). (3) To assess carotid stenosis, angiography or multi-
ple-slice helical contrast material–enhanced computed to-
mography (angio-CT) was performed in patients who met
the surgical criteria for color flow imaging. These criteria
were set according to the American Heart Association
guidelines for carotid endarterectomy.18 (4) AAAs were
assessed with both echo-tomography and contrast-enhanced CT. An aneurysm was defined as an increase of at
least 150% in mean vessel diameter compared with the
diameter of the immediately adjacent segment. Aneurysm
diameter was measured on CT scans and compared with
data on each surgical report.
Among the 76 patients with PAOD, Fontain disease
stage was IIa in 21 patients, IIb in 38 patients, III in 15
patients, and IV in 4 patients.
According to the epidemiologic findings for AAA re-
ported by Blanchard et al,19 only cigarette smoking and
arterial hypertension were considered risk factors for this
disease.
Hypertension was defined according to the American
Heart Association guidelines for the management of hyper-
tension.20 Smoker definition included both ex-smokers
and active smokers.
Whole blood (3 mL) from patients and control subjects
was collected into potassium ethylenediaminetetraacetic acid.
DNA was prepared with an Istagene Matrix extraction kit
(Bio-Rad Laboratories). The polymerase chain reaction for
CCR5 was carried out in a total volume of 25 L, with 5 L
of extracted genomic DNA; 100 mol/L of deoxyadenosine
triphosphate, deoxyguanosine triphosphate, deoxythymodine
triphosphate, and deoxycytidine triphosphate; 1.5 mmol/L
of magnesium chloride; 1 unit of Taq polymerase; and the 2
primers, forward and reverse, each at a concentration of 80
nmol/L. The primers were designed with Primer Express
software. The CCR5 primer sequence is forward primer
5=-CTGTGTTTGCGTCTCTCCCA-3=; reverse primer
5=-CCTCTTCTTCTCATTTCGACACCG-3=. The poly-
merase chain reaction was started with 10 minutes of incuba-
tion at 94°C to activate the enzyme, followed by 35 cycles of
20 seconds at 94°C, 20 seconds at 55°C, and 30 seconds at
72°C. The amplification was verified on agarose gel (3%).
Differences between groups were examined with the 2
test. Odds ratios (OR; approximate relative risk) were cal-
culated as an index of the association of the CCR5 geno-
type with each phenotype. For each OR, 2-tailed proba-
bility values and 95% confidence intervals (CI) were calcu-
lated. Multivariate logistic regression was used to evaluate
the strength of the association between 32 deletion and
AAA, ruptured AAA in particular, to eliminate any possible
confounding effects of hypertension, gender, or smoking.
All statistical analyses were 2-sided, and were performed
with Stata Statistical Software.
RESULTS
Demographic data and distribution of the 380 patients
are shown in Table I. Gender frequency was different
among the AAA, PAOD, carotid stenosis, and control
groups. Hypertension was significantly more common in
patients with AAA than in any other group (control sub-
jects, P .0001; carotid stenosis group, P .0047; PAOD
group, P  .047). Comparison of PAOD and carotid
stenosis groups with the control group revealed that smok-
ing and hypertension were significantly more common in
patient groups than in the control group. The polymor-
phism distribution in patients and control subjects was in
rs and
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Weinberg equilibrium model (Table II).
In patients with AAA the 32 allelic variation was
significantly different compared with that in control sub-
jects (P  .002; OR, 2.7; 95% CI, 1.32-5.47; AAA vs
control subjects, 32 vs wild type [WT]). ORs associated
with the presence of a genotype with at least 1 32 allele
(WT/32  32/32 vs WT/WT genotype) was 2.83
(95% CI, 1.32-5.47; P .0029). Therefore the presence of
the 32 allele seems to be more common in patients with
AAAs than in control subjects.
The increased presence of this allele significantly differ-
entiates AAA from both PAOD and carotid stenosis (Table
II; OR, 2.77 and 3.47, respectively). No differences were
Table I. Demographic data for patients with AAA, PAOD
PAOD
t test P
Age (y)
AAA 716 1.714768 .088
PAOD 689
CS 698
Control subjects 687
2 test P
Sex (M:F)
AAA 61:9 2.8338 .092
PAOD 58:18 —
CS 34:28 —
Control subjects 112:60 —
Hypertension
AAA 55/15 7.9863 .004
PAOD 43/33
CS 39/23
Control subjects 65/104
Smoker (exsmoker)
AAA 47 (7)/23 0.4726 .491
PAOD 55 (3)/21
CS 45 (9)/17
Control subjects 97 (3)/75
AAA, Abdominal aortic aneurysm; PAOD, peripheral arterial occlusive dise
*Age, gender, hypertension, and smoking habits were considered risk facto
Table II. CCR5 genotype and frequency of 32 mutation
Genotype AAA PAOD
WT/WT 51 67
OR 1
WT/32 18 9
OR —
32/32 1 0
OR —
WT/32  32/32 19 9 .
OR 2.77
95% CI 1.07-7.52
32 frequency .14 .06 .
OR 2.64
95% CI 1.09-6.84
AAA, Abdominal aortic aneurysm; PAOD, peripheral arterial occlusive diseobserved in either allele or genotype distribution amongpatients with PAOD or carotid stenosis and control sub-
jects.
Among the AAA group, patients with at least 1 32
allele are at 4-fold higher risk for AAA rupture compared
with WT/WT carriers (Table III).
No significant differences in aneurysm diameter were
observed in WT and 32 allele carriers (WT/WT 53/
22.3 mm vs WT/32  32/32 47.1/15.6 mm,
mean  SD; P  .08).
Multiple logistic regression analysis was performed to
identify possible independent risk factors for AAA between
patients and control subjects and between the AAA group
and both the PAOD and carotid stenosis groups. The
PAOD and carotid stenosis groups were considered as a
CS and for control subjects*
CS Control subjects
t test P t test P
1.153986 .250627 2.398307 .017236
0.488193 .6262 0 1
0.645267 .519397
2 test P 2 test P
17.0081 .0001 11.8424 .0006
7.0874 .0078 3.0665 .0799
— 2.0515 .1521
— —
3.9372 .0472 31.8535 .0001
0.5664 .4517 6.9809 .0082
10.9475 .009
0.4603 .4975 2.3849 .1225
0.0008 .9779 5.6683 .0173
5.0038 .0253
S, carotid stenosis.
were compared among the 4 groups.
atients and control subjects
Carotid
stenosis P
Control
subjects P
56 152
1 1
6 20
— —
0 0
— —
6 .01 .009
3.57 20
1.20-11.39 1.31-6.06
.05 .00
3.27 2.7
1.20-10.28 1.32-5.47
T, wild type; OR, odds ratio; CI, confidence interval., or
539
3
7
8
ase; Cin p
P
019
017whole, given the common characteristic of stenosis of the
depen
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arterial disease. Finally, multiple logistic regression analysis
was performed to identify possible independent risk factors
for ruptured AAA (Table IV). Although 32 deletion
mutation was significantly different between AAA and con-
trol groups in this series, it does not seem to be an inde-
pendent risk factor for AAA (P .064), but there is a trend
toward significance.
When patients are considered, the presence of 32
allele is an independent risk factor that significantly differ-
entiates patients with AAA from those with PAOD or
carotid stenosis (P  .012). Furthermore, within the AAA
group the 32 allele is an independent risk factor for
rupture (P .045), whereas hypertension, cigarette smok-
ing, and gender are not involved in this life-threatening
complication.
DISCUSSION
Atherosclerosis is a progressive multifactorial vascular
disease characterized in part by the early and persistent
presence of macrophages, T lymphocytes, and vascular
dendritic cells within arterial walls.21-24 These cellular pop-
ulations are involved in the chronic inflammatory process
that has a role in the pathogenesis of atherosclerosis.25 The
AAA wall is also characterized by a chronic inflammatory
infiltrate.
However, there is evidence that the 2 processes affect
Table III. CCR5 genotype and 32 mutation frequency
Genotype
Ruptured
(N  21)
n % n
WT/WT 11 52 40
WT/32 10 48 8
32/32 0 1
WT/32  32/32 10 48 9
32 frequency 0.24 0.
WT, Wild type; OR, odds ratio; CI, confidence interval.
Table IV. Multiple logistic regression analysis
Variable
AAA vs control subjects 32
Cigarette smok
Hypertension
Sex (male)
AAA vs PAOD  CS 32
Hypertension
Cigarette smok
Sex (male)
Ruptured vs elective AAA repair 32
Cigarette smok
Hypertension
Sex (male)
Only statistically significant variables are reported. CCR5 32 allele is an in
AAA, Abdominal aortic aneurysm; PAOD, peripheral arterial occlusive disedistinct layers of the arterial wall; atherosclerosis mainlyinvolves the inner layers, intima, and media, whereas AAA
typically affects the outer layers, media, and adventitia.26
Inflammatory infiltration by macrophages and lympho-
cytes is a common underlying factor in the pathogenesis of
atherosclerosis and AAA. As a consequence, both diseases
may be considered a response to an injury that develops in
2 distinct directions. Atherosclerosis is linked with wall
thickening and reduction of the arterial lumen, whereas
AAA is linked with wall thinning and enlargement of the
arterial lumen, partially attenuated by thrombus deposi-
tion.
Inflammatory cell infiltration of the arterial wall acti-
vates a cascade of enzymes involved as mediators of inflam-
mation. Chemokines have a key role in cellular recruitment,
and induction of expression and activation of several en-
zymes involved in extracellular matrix remodeling and me-
tabolism, in particular, matrix metalloproteinases and their
inhibitors.25,26 CC chemokine receptors are important
modulators of inflammation. Although CC chemokine re-
ceptors have been found predominantly on leukocytes,
recent studies have suggested that vascular muscle cells
respond to CC chemokines.27
Reed et al28 described the similarity of risk factors for
occlusive and aneurysmal diseases in a sample of 8000 men,
and concluded that atheroma is a causal pathway to aneu-
rysm development. The usual occlusive forms of atheroma
involve intimal accumulation of material (eg, lipids, matrix
tients with ruptured and elective AAA repair
ve repair
 49)
OR 95% CI P%
82
16
2
18 4.04 1.13-14.30 .011
2.75 0.92-8.08 .035
OR 95% CI P
2.17 0.95-4.96 .064
2.56 1.01-9.27 .047
5.06 2.94-10.94 .001
4.02 1.56-3.78 .002
3.13 1.33-7.33 .012
2.54 1.15-5.60 .008
1.65 0.74-3.65 .21
3.26 1.36-7.81 .008
3.52 1.01-11.80 .045
0.48 0.11-2.05 .325
0.42 0.11-1.60 .209
1.30 0.26-6.51 .74
dent risk factor for dilatative arterial disease and AAA rupture.
S, carotid stenosis; OR, odds ratio; CI, confidence interval.in pa
Electi
(N
10ing
ing
ingproteins, cells), whereas the medial layer, which consists of
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 5 Ghilardi et al 999smooth muscle cells and insoluble extracellular matrix,
remains largely uninjured, In contrast, aneurysm develop-
ment involves proteolytic injury to the medial layer. These
injuries include degradation of elastin and collagen, smooth
muscle cell rarefraction, and compensatory fibrosis of the
adventitia.
The change in atheroma evolution toward aneurysm
development might be determined in part by genetic back-
ground.29 Genetic susceptibility to aneurysm development
from atherosclerotic disease may be associated with poly-
morphisms located on candidate genes. Our study proposes
CCR5 polymorphism as 1 of these candidate genes. In-
deed, our results show that the 32 deletion differentiates
AAA from both PAOD and carotid stenosis.
Furthermore, almost 50% of patients with ruptured
aneurysms in our series were 32 allele carriers; patients
with AAA heterozygous for32 are at 4-fold higher risk for
aneurysm rupture. Although this series is not large enough
to enable definitive conclusions, it is remarkable that the
association between the presence of the 32 allele in pa-
tients with AAAs electively operated on and ruptured AAAs
raises statistical significance, both for genotype distribution
(P .011) and allele frequency (P .035), in the sense of
a tendency to rupture in 32 carriers (Table III).
These results seem to be somewhat reinforced when the
diameter of AAAs is concerned, because ruptured AAAs
showed a tendency toward mean diameter smaller than
electively repaired AAAs (P .08). If confirmed in further,
larger studies, these results would implicate CCR5 signal-
ing as having an important role in facilitating rupture of
AAAs.
Recent studies suggest that individuals homozygous
for 32 are at reduced risk for coronary artery disease,
although this allele does not have an apparent protective
effect in the heterozygous form.16
32 mutation causes truncation and loss of CCR5
receptors on lymphoid cell surface. The possibility that
CCR5 ligands (regulated on activation, T-cell expressed
and secreted [RANTES], macrophage inflammatory
protein-1	, macrophage inflammatory protein-1
) are in-
volved in development of atherosclerosis suggests that the
absence of this receptor might reduce the risk for suscepti-
bility to the disease. Kuziel et al30 demonstrated that the
early stages of plaque formation in apolipoprotein E knock-
out mice do not depend on CCR5.
Another hypothesis suggests that Th1 immune re-
sponses appear to predominate in human arterial occlu-
sive lesions31 and that in turn AAA predominantly ex-
press Th2-associated cytokines.32 Correspondingly in
AAA, there is a decrease in or absence of mediators
associated with Th1 response, in particular the interfer-
on- signaling pathway. Furthermore, it was demon-
strated that Th1 CD4 lymphocytes preferentially ex-
press CCR5 and CXCR3.33 The results of our study
suggest that in AAA there is a decrease in or absence of
the CCR5-mediated pathway as well. This finding could
support the possibility that immune response is involved,
to some degree, in formation and development of AAA;a 40 kDa chemoattractant protein (AAAP-40) and im-
munoglobulin G were found within the wall of AAAs in
human beings.26,33
Because persons with inactive CCR5 seem to be other-
wise healthy, it appears that complete or partial blockage of
CCR5 is not detrimental. There are no obvious abnormal-
ities in these individuals, and the frequency of the inactive
or deleted allele appears in certain populations to approach
10% to 20%. The discovery of CCR5-deprived healthy
persons raises the question of what this receptor does. The
answer would provide as much insight into the physiologic
characteristics of chemokines as the pathophysiologic fea-
tures of atherosclerosis and AAA.
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